Clinical Trial: Activation of a Cutaneous Inflammasome in the Skin of Hidradenitis Suppurativa Patients

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: ex Vivo Study of the Inflammatory Response Associated With Hidradenitis Suppurativa

Brief Summary:

The objective is to investigate ex vivo the inflammatory response in hidradenitis suppurativa (HS) (activation of an inflammasome, role of pro-inflammatory cytokines) in the skin of patients treated surgically for this disease.

The investigators hypothesize that Th17-derived cytokines, especially Interleukin (IL) IL-17, could serve as a relay in the inflammatory process leading to HS severity and recurrences.


Detailed Summary:

The objective is to investigate ex vivo the inflammatory response in hidradenitis suppurativa (activation of an inflammasome, role of pro-inflammatory cytokines) in the skin of patients treated surgically for this disease.

The investigators hypothesize that Th17-derived cytokines, especially IL-17, could serve as a relay in the inflammatory process leading to HS severity and recurrences.To fulfil this proposal, the investigators will aim at demonstrating and characterizing the presence of an inflammasome associated to HS disease - Hypothesis It is widely accepted that hyperkeratinisation and follicular occlusion originate infection thereof causing skin inflammation. The investigators here hypothesized that host-derived danger signals led to the release of inflammatory mediators such as IL-1β by activating an inflammasome structure.

The inflammasome is a molecular platform controlling the expression and the activation of IL-1β via different sensors. The proinflammatory cytokine IL-1β could subsequently lead to the recruitment and orientation of lymphocytes towards a Th17 subtype creating a feedback loop maintaining excessive tissue inflammation in HS.

If such a complex inflammatory process is present in HS, blocking both the bacterial-induced (IL-1 β) and the sterile-associated (IL-17) inflammation would largely improve the therapeutic benefit for HS patients.

- Experimental approach

The investigators will seek to highlight the presence of inflammasome sensors and effectors in skin explants from HS compared to control skin. For this original physiopathological study, 10 lesional skins excised from HS patients or controls (plastic surgery) after they signed
Sponsor: CHU de Reims

Current Primary Outcome:

  • cytokine quantification (IL1-β) by ELISA [ Time Frame: up to 4 days ]
  • cytokine quantification (IL-10) by ELISA [ Time Frame: up to 4 days ]
  • cytokines quantification (IL-13) by ELISA [ Time Frame: up to 4 days ]
  • cytokines quantification (IL-18) by ELISA [ Time Frame: up to 4 days ]
  • cytokines quantification (CXCL10) by ELISA [ Time Frame: up to 4 days ]
  • cytokines quantification (TNFα) by ELISA [ Time Frame: up to 4 days ]
  • cytokines quantification (TGFβ) by ELISA [ Time Frame: up to 4 days ]


Original Primary Outcome: cytokines quantification (IL1-β, IL-10, IL-13, IL-18, CXCL10, TNFα, TGFβ) by ELISA [ Time Frame: up to 4 days ]

Current Secondary Outcome:

Original Secondary Outcome:

Information By: CHU de Reims

Dates:
Date Received: July 4, 2016
Date Started: March 2015
Date Completion:
Last Updated: July 15, 2016
Last Verified: July 2016